Mark Plavsic
Chief Tech/Sci/R&D Officer chez AURA BIOSCIENCES, INC.
Fortune : 2 M $ au 31/03/2024
Profil
Le Dr Mark Plavsic est directeur technique chez Fate Therapeutics, Inc. Auparavant, le Dr. Plavsic était employé comme directeur technique par Lysogene SA et comme chef du développement et de la fabrication des processus par Torque Therapeutics, Inc. Il a obtenu son diplôme d'études supérieures de l'Université de Belgrade et un doctorat de l'Université de Belgrade.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
AURA BIOSCIENCES INC
0,26% | 15/03/2024 | 128 515 ( 0,26% ) | 1 M $ | 31/03/2024 |
FATE THERAPEUTICS, INC.
0,12% | 10/01/2023 | 123 705 ( 0,12% ) | 907 995 $ | 31/03/2024 |
Postes actifs de Mark Plavsic
| Sociétés | Poste | Début |
|---|---|---|
| AURA BIOSCIENCES, INC. | Chief Tech/Sci/R&D Officer | 02/10/2023 |
TeraPore Technologies, Inc.
 TeraPore Technologies, Inc. Chemicals: SpecialtyProcess Industries TeraPore Technologies, Inc. develops cutting-edge membrane technologies for high-permeability, high-resolution nanofiltration. The company was founded by Rachel Dorin in 2013 and is headquartered in | Director/Board Member | - |
Anciens postes connus de Mark Plavsic
| Sociétés | Poste | Fin |
|---|---|---|
| FATE THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 06/03/2023 |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - |
Torque Therapeutics, Inc.
 Torque Therapeutics, Inc. BiotechnologyHealth Technology Torque Therapeutics, Inc. develops immunotherapies to address cancers focused on the specific modulation of immune cell subsets. The company was founded by Bart Henderson, Ulrik B. Nielsen, Darrell J. Irvine, and Thomas Lars Andresen and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - |
| LYSOGENE | Chief Tech/Sci/R&D Officer | - |
Formation de Mark Plavsic
| University of Belgrade | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| AURA BIOSCIENCES, INC. | Health Technology |
| FATE THERAPEUTICS, INC. | Health Technology |
| LYSOGENE | Commercial Services |
| Entreprise privées | 3 |
|---|---|
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
Torque Therapeutics, Inc.
Torque Therapeutics, Inc. BiotechnologyHealth Technology Torque Therapeutics, Inc. develops immunotherapies to address cancers focused on the specific modulation of immune cell subsets. The company was founded by Bart Henderson, Ulrik B. Nielsen, Darrell J. Irvine, and Thomas Lars Andresen and is headquartered in Cambridge, MA. | Health Technology |
TeraPore Technologies, Inc.
TeraPore Technologies, Inc. Chemicals: SpecialtyProcess Industries TeraPore Technologies, Inc. develops cutting-edge membrane technologies for high-permeability, high-resolution nanofiltration. The company was founded by Rachel Dorin in 2013 and is headquartered in | Process Industries |
